Recipharm notes an increased demand for Chloroquine Phosphate

Report this content

Recipharm, a leading contract development and manufacturing organisation (CDMO), has recently noted an increase in demand for its product Klorokinfosfat RPH Pharma marketed in Sweden by Astimex Pharma. The CDMO has also received questions about the product, which is typically used to treat patients with malaria prophylaxis and rheumatoid arthritis. The reason for the interest in this well-known product is due to chloroquine's antiviral effects, which mean it has been mentioned as a drug that can potentially be used when treating patients with coronavirus COVID-19 associated pneumonia. Furthermore, chloroquine has been included by WHO as one drug treatment option for priority research connected to immediate goals (

Although Klorokinfosfat RPH Pharma is not approved as an antiviral agent or for use in relation to pneumonia, Recipharm is presently focussing on securing supply of its chloroquine product in case the demand suddenly increases and new recommendations are introduced. Because of the current situation with the new coronavirus we believe it is of utmost importance to take every measure to be prepared.

Contact information
Jean-François Hilaire, Executive Vice President Strategy & Global Integration,, + 33 695 447 507
Chris Hirst, General Manager, RPH Pharmaceuticals AB,, + 44 (0) 754 551 3567

For media enquiries, please contact Lindsay Baldry at ramarketing:, + 44 (0)191 222 1242,, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.5 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit   

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00